Amedica Corporation announced the release of its Valeo II™ C interbody fusion device system. The second generation cervical system will be commercially available mid-February 2016. The Valeo II C interbody fusion device, made entirely of Amedica's micro composite silicon nitride biomaterial, offers a slim-profile design which improves intraoperative visibility for more exact placement and postoperative visibility, providing better assessment of successful fusion.

The new design also includes directional teeth to resist expulsion, an anterior thread connection for improved inserter stability, and a 14x12mm footprint size for smaller patients. Accompanying the revised implants are new consolidated, single-level instrumentation sets with improved ergonomics and ease of use. The Valeo II C interbody fusion device is made of micro composite silicon nitride biomaterial, which offers a favorable environment for bone growth and osteointegration, when compared to competitive PEEK and titanium offerings.

Valeo II silicon nitride interbody fusion devices are also semi-radiolucent with clearly visible boundaries in x-rays and produce no artifacts under MRI or CT scans. The combination of these properties is found only in Amedica's silicon nitride biomaterial technology. The Valeo C family of products is the first to receive FDA clearance for two-level cervical interbody cage indications.

Valeo cervical fusion devices are indicated for use in skeletally mature patients with degenerative disc disease at one disc level or two contiguous levels and are designed for use with autograft or allograft to facilitate fusion.